The abstract is read at the publisher; the summary is JClub's.
Across 78 randomized heart failure trials (292,027 patients; 28.1% women), treatment efficacy shows no sex difference, with delta ln[REM] 0.00 (95% CI -0.04 to 0.03; P = .85).
- Why it matters: Women are underrepresented in heart failure trials, leaving uncertainty about whether sex-specific treatment effects might be missed when results are pooled.
- What they did: A systematic search to 21 March 2025 identified 139 RCTs (≥100 patients) of pharmacological HF treatments versus placebo or usual care, using random-effects meta-analysis of relative effect measures and meta-regression by women’s enrollment proportion.
- The result: Meta-regression across 78 RCTs found no link between women’s proportion and sex differences in REMs (P = .25), and no association for overall efficacy across 139 RCTs (P = .24), implying sex balance likely did not mask major differences.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.